Danaher (DHR) Stock Analysis & AI Equity Report
Danaher (DHR) overview
Danaher (DHR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 24,568m and operating profit of USD 4,690m; the year-end share price was 228.92 USD and market capitalisation was USD 161,824m. Danaher is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Danaher's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Danaher
Danaher is a science and technology company with operating businesses in biotechnology, life sciences and diagnostics. Its biotechnology segment supplies equipment, consumables, software and services used in the research, development, manufacture and delivery of biological medicines, including vaccines, proteins and cell and gene therapies. Its businesses serve customers through recurring and nonrecurring sales.
Generate the Danaher report
Danaher is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Danaher and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Danaher
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.